Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 13/20 | 0.67 |
| ▸ | KDR | P35968 | 9/20 | 0.67 |
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | MET | P08581 | 5/20 | 0.63 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371902 | 1.00 | PDGFRA (0.67) | PDGFRAKDRKITMETAXL | |
| SCHEMBL20525577 | 0.92 | PDGFRA (0.66) | PDGFRAKDRKITMETAXL | |
| SCHEMBL372068 | 0.92 | PDGFRA (0.68) | PDGFRAKDRKITMETAXL | |
| SCHEMBL372067 | 0.92 | PDGFRA (0.68) | PDGFRAKDRKITMETAXL | |
| SCHEMBL13210880 | 0.92 | PDGFRA (0.68) | PDGFRAKDRKITMETAXL | |
| SCHEMBL371843 | 0.89 | PDGFRA (0.64) | PDGFRAKDRKITMETAXL | |
| SCHEMBL29693572 | 0.89 | PDGFRA (0.64) | PDGFRAKDRKITMETAXL | |
| SCHEMBL371842 | 0.89 | PDGFRA (0.64) | PDGFRAKDRKITMETAXL | |
| SCHEMBL29693604 | 0.85 | PDGFRA (0.64) | PDGFRAKDRKITMETAXL | |
| SCHEMBL372059 | 0.85 | PDGFRA (0.64) | PDGFRAKDRKITMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | claimed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885KIT 5/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885KIT 5/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885KIT 5/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885KIT 5/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885KIT 5/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | PDGFRA 182/4885KDR 5/4885KIT 4/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885KIT 5/4885 |
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRA 182/4885KDR 5/4885KIT 4/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRA 182/4885KDR 5/4885KIT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.